Response to Variables Affecting the Potential Efficacy of Platelet-Rich Plasma in Dermatology

The authors of the document responded to Sharun et al.'s comments on their research letter regarding the use of platelet-rich plasma (PRP) in lichen planopilaris (LPP) and its variants. They provided additional details about their PRP protocol, which involves obtaining 8-16 mL of whole blood, centrifuging it to yield 5-10 mL of PRP, and administering 50-100 injections across the affected scalp. The authors agreed that variability in PRP procedures could affect efficacy and concluded that while koebnerization was not observed in their patient cohort, PRP injection therapy did not show a significant response in treating LPP and its variants. They did not recommend PRP as monotherapy for these conditions and emphasized the need for randomized controlled trials (RCTs) to truly assess the efficacy and safety of PRP injections in LPP and its variants, noting that current RCTs are mostly limited to androgenetic alopecia.